Autism: A target of pharmacotherapies?

Drug Discovery Today

Volumn 9, Issue 8, 2004, Pages 366-374

  Gerlai, Robert ^a   Gerlai, Julia ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

Alzheimer's disease; Autism spectrum disease; Biochemistry; Brain disorders; Candidate loci; Disease genes; Disease mechanisms; Drug Discovery; Molecular Medicine; Neurobiology; Pharmaceutical Science; Pharmacotherapies

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; HISTAMINE H1 RECEPTOR ANTAGONIST; NALTREXONE; OLANZAPINE; OPIATE ANTAGONIST; PIMOZIDE; RISPERIDONE; SECRETIN; SEROTONIN 1A AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

AGGRESSION; AUTISM; BEHAVIOR; BRAIN DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IRRITABILITY; MOLECULAR MECHANICS; NEUROTRANSMISSION; NONHUMAN; REVIEW; SENSORIMOTOR FUNCTION; SIDE EFFECT;

ANIMALS; AUTISTIC DISORDER; DISEASE MODELS, ANIMAL; HUMANS; MUTATION; NEUROTRANSMITTER AGENTS;

EID: 1842635431     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03039-9     Document Type: Review

References (95)

1. Nash M.J. The secrets of autism. Time. 159:2002;46-56.
2. Stokstad E. New hints into the biological basis of autism. Science. 294:2001;34-37.
3. Tager-Flusberg H., et al. Current directions in research on autism. Ment. Retard. Dev. Disabil. Res. Rev. 7:2001;21-29.
4. Powers, M.D. (2000) What is autism? In Children with Autism: a Parents' Guide (2nd edn), (Powers, M.D. ed.) pp. pp.1-44, Woodbine House, Bethesda, MD
5. DSM-IV-TR. Diagnostic and Statistical Manual of Mental Disorders. 4th edn:2000;70-76 American Psychiatric Association.
6. LeCouter A., et al. Autism diagnostic interview: a semi-structured interview for parents and caregivers of autistic persons. J. Autism Dev. Disord. 19:1989;363-387.
7. Lord C., et al. Autism diagnostic interview- revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J. Autism Dev. Disord. 24:1994;659-685.
8. DiLavore P., et al. Pre-linguistic autism diagnostic observation schedule (PL-ADOS). J. Autism Dev. Disord. 25:1995;355-379.
9. Lord C., et al. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J. Autism Dev. Disord. 30:2000;205-223.
10. Kanner L. Autistic disturbances of affective contact. Nervous Child. 2:1943;217-250.
11. Wing, L. (1997) Syndromes of autism and atypical development. In Handbook of Autism and Pervasive Developmental Disorders (2nd edn), (Cohen D.J. and Volkmar F.R. eds) pp 148-170, John Wiley, New York
12. Wing L. Asperger's syndrome: a clinical account. Psychol. Med. 11:1981;115-129.
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th edn:1994;APA, Washington DC.
14. Filipek P.A., et al. Practice parameter: screening and diagnosis of autism. Neurology. 55:2000;468-479.
15. The MIND Institute Newsletter (2002) Winter 2002/03:3
16. Rapin I. The autistic spectrum disorders. N. Engl. J. Med. 347:2002;302-303.
17. Cade M., Tidwell S. Autism and the school nurse. J. Sch. Health. 71:2001;96-100.
18. Yeargin-Allsopp M., et al. Prevalence of autism in a US metropolitan area. J.A.M.A. 289:2003;49-55.
19. DeStefano F. Vaccines and autism. Pediatr. Infect. Dis. J. 20:2001;887-888.
20. Hornig M., Lipkin W.I. Infectious and immune factors in the pathogenesis of neurodevelopmental disorders: epidemiology, hypotheses, and animal models. Ment. Retard. Dev. Disabil. Res. Rev. 7:2001;200-221.
21. Korvatska E., et al. Genetic and immunologic considerations in autism. Neurobiol. Dis. 9:2002;107-125.
22. Kaminska B., et al. Use of secretin in the treatment of childhood autism. Med. Sci. Moni. 8:2002;RA22-RA26.
23. Knivsber A.M., et al. Reports on dietary intervention in autistic disorders. Nutr. Neurosci. 4:2001;25-37.
24. Singh V.K., et al. Serological association of measles virus and human herpesvirus-6 with brain autoantibodies in autism. Clin. Immunol. Immunopathol. 89:1998;105-108.
25. Binstock T. Intra-monocyte pathogens delineate autism subgroups. Med. Hypotheses. 56:2001;523-531.
26. Afzal M.A., et al. Measles virus persistence in specimens of inflammatory bowel disease and autism cases. Dig. Dis. Sci. 46:2001;658-660.
27. Strömland K., et al. Autism in thalidomide embryopathy: a population study. Dev. Med. Child Neurol. 36:1994;351-356.
28. Fein D., et al. Pitocin induction and autism. Am. J. Psychiat. 154:1997;438-439.
29. Tilson H.A. Neurochemical effects of PCBs - an overview. Neurotoxicol. 18:1997;727-744.
30. Harris, S. and Handelman, J. (1994) Preschool Education Programs for Children with Autism, Pro-Ed, TX
31. Lovaas, I. (1981) Teaching Developmentally Disabled Children: The Me Book, Pro-Ed, TX
32. Schopler E. Parent Survival Manual. 1995;Plenum Press, NY.
33. Rubenstein J.L.R., Merzenich M.M. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2:2003;255-267.
34. Folstein S., Santangelo S. Does Asperger syndrome aggregate in families? Klin A., et al. Asperger Syndrome. 2000;159-171 Guilford Press, New York.
35. Bailey A., et al. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol. Med. 25:1995;63-77.
36. Rutter M., et al. Genetics and child psychiatry: II empirical research findings. J. Child Psychol. Psychiatry. 40:1999;19-55.
37. Gerlai J., Gerlai R. Autism: a large unmet medical need and a complex research problem. Physiol. Behav. 79:2003;461-470.
38. Lai C.S.L., et al. The SPCH1 region on human 7q31: genomic characterization of the critical interval and localization of translocations associated with speech and language disorder. Am. J. Hum. Genet. 67:2000;357-368.
39. Fisher S.E., et al. Localisation of a gene implicated in severe speech and language disorder. Nat. Genet. 18:1998;168-170.
40. Cook E.H., Leventhal B. The serotonin system in autism. Curr. Opin. Pediatr. 8:1996;348-354.
41. Betancur C., et al. Serotonin transporter gene polymorphisms and hyperserotonemia in autistic disorder. Mol. Psychiatry. 7:2002;67-71.
42. McDougle C.J., et al. A double-blind, placebo controlled study of fluvoxamine in adults with autistic disorder. Arch. Gen. Psychiatry. 53:1996;1001-1008.
43. Wassink T.H., et al. Evidence supporting WNT2 as an autism susceptibility gene. Am. J. Med. Genet. 105:2001;406-413.
44. Fatemi S.H. Reelin mutations in mouse and man: from reeler mouse to schizophrenia, mood disorders, autism and lissencephaly. Mol. Psychiatry. 6:2001;129-133.
45. Cheadle J.P., et al. Molecular genetic advances in tuberous sclerosis. Hum. Genet. 107:2000;97-114.
46. Nellist M., et al. Characterization of the cytosolic tuberin-harmatin complex. Tuberin is a cytosolic chaperone for hamartin. J. Biol. Chem. 274:1999;35647-35652.
47. Warren S.T., Sherman S.L. The fragile X syndrome. Sciver C.R. The Metabolic and Molecular Basis of Inherited Disease. 8th edn:2000;McGraw-Hill, New York.
48. Feinstein C., Reiss A.L. Autism: the point of view from fragile X studies. J. Autism Dev. Disord. 28:1998;393-405.
49. Jamain S., et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat. Genet. 34:2003;27-29.
50. Turner G., et al. Variable expression of mental retardation, autism, seizures, and dystonic hand movements in two families with an identical ARX genemutation. Am. J. Med. Genet. 112:2002;405-411.
51. Jiang Y., et al. Genetics of Angelman syndrome. Am. J. Hum. Genet. 65:1999;1-6.
52. Shao Y., et al. Fine mapping of autistic disorder to chromosome 15q11-q13 by use of phenotypic subtypes. Am. J. Hum. Genet. 72:2003;539-548.
53. Blatt G.J., et al. Density amd distribution of hippocampal neurotransmitter receptors in autism: an autoradiographic study. J. Autism Dev. Disord. 31:2001;537-544.
54. Hérault J., et al. Serotonin and autism: biochemical and molecular biology features. Psychiatry Res. 65:1996;33-43.
55. Hunsinger D.M., et al. Is there a basis for novel pharmacotherapy of autism? Life Sci. 67:2000;1667-1682.
56. Carlsson M.L. Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamate - serotonin interactions for pharmacotherapy. J. Neural Transm. 105:1998;525-535.
57. Jamain S., et al. Linkage and association between glutamate receptor 6 and autism. Mol. Psychiatry. 7:2002;302-310.
58. Stone R.L., et al. A mutation in adenylosuccinate lyase associated with mental retardation and autistic features. Nat. Genet. 1:1992;59-63.
59. Bottini N., et al. Autism: evidence of association with adenosine deaminase genetic polymorphism. Neurogenetics. 2:2001;111-113.
60. Persico A.M., et al. Adenosine deaminase alleles and autistic disorder: case-control and family-based association studies. Am. J. Med. Genet. 96:2000;784-790.
61. Green L., et al. Oxytocin and autistic disorder: alterations in peptide forms. Biol. Psychiatry. 50:2001;609-613.
62. Insel T.R., et al. Oxytocin, vasopressin, and autism: is there a connection? Biol. Psychiatry. 45:1999;145-157.
63. Modahl C., et al. Plasma oxytocin levels in autistic children. Biol. Psychiatry. 43:1998;270-277.
64. Nelson K.B., et al. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann. Neurol. 49:2001;597-606.
65. Purcell A.E., et al. The abnormal regulation of gene expression in autistic brain tissue. J. Autism Dev. Disord. 31:2001;545-549.
66. McCracken J.T., et al. Risperidone in children with autism and serious behavioral problems. N. Engl. J. Med. 347:2002;314-321.
67. Posey D.J., McDougle C.J. The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harv. Rev. Psychiatry. 8:2000;45-63.
68. Beglinger L.J., Smith T.H. A review of subtyping in autism and proposed dimensional classification model. J. Autism Dev. Disord. 31:2001;411-422.
69. Junaid M.A., Pullarkat R.K. Proteomic approach for the elucidation of biological defects in autism. J. Autism Dev. Disord. 31:2001;557-560.
70. Yonan A.L., et al. Bioinformatic analysis of autism positional candidate genes using biological databases and computational gene network prediction. Genes Brain Behav. 2:2003;303-320.
71. Moy, S.S. et al. Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice, Genes Brain Behav. (in press)
72. Gerlai R. and Clayton, N.S. (1999) Analysing hippocampal function in transgenic mice: an ethological perspective, Trends Neurosci. 22, 47-51
73. Andres C. Molecular genetics and animal models in autistic disorder. Brain Res. Bull. 57:2002;109-119.
74. Buxbaum J.D., et al. Association between a GABRB3 polymorphism and autism. Mol. Psychiatry. 7:2002;311-316.
75. Winslow J.T., Insel T.R. The social deficits of the oxytocin knockout mouse. Neuropeptides. 36:2002;221-229.
76. Petit E., et al. Association study with two markers of a human homeogene in infantile autism. J. Med. Genet. 32:1995;269-274.
77. Millen K.J., et al. Abnormal embryonic cerebellar development and patterning of postnatal foliation in two mouse Engrailed-2 mutants. Development. 120:1994;695-706.
78. Joyner A.L., et al. Subtle cerebellar phenotype in mice homozygous for a targeted deletion of the En-2 homeobox. Science. 251:1991;1239-1243.
79. Kobayashi T., et al. Transgenic rescue from embryonic lethality and renal carcinogenesis in the Eker rat model by introduction of a wild-tupe Tsc2 gene. Proc. Natl. Acad. Sci. U. S. A. 94:1997;3990-3993.
80. Pasumarthi K.B., et al. Enhanced cardcardiomyocyte DNA synthesis during myocardial hypertrophy in mice expressing a modified Tsc2 transgene. Circ. Res. 86:2000;1069-1077.
81. D'Hooge R., et al. Mildly impaired water maze performance in male Fmr1 knockout mice. Neuroscience. 76:1997;367-376.
82. Kooy R.F., et al. Transgenic mouse model for the fragile X syndrome. Am. J. Med. Genet. 64:1996;241-245.
83. Oostra B.A., Hoogeeveen A.T. Animal model for fragile X syndrome. Ann. Med. 29:1997;563-567.
84. Peier A.M., et al. (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum. Mol. Genet. 9:2000;1145-1159.
85. Gerlai R., et al. Impaired motor learning performance in cerebellar En-2 mutant mice. Behav. Neurosci. 110:1996;126-133.
86. Engelmann M., Landgraf R. Microdialysis administration of vasopressin into the septum improves social recognition in Brattleboro rats. Physiol. Behav. 55:1994;145-149.
87. Lijam N., et al. Social interaction and sensorimotor gating abnormalities in mice lacking Dvl1. Cell. 90:1997;895-905.
88. Falconer D.S. Two new mutants, trembler and 'Reeler', with neurological actions in the house mouse. J. Genet. 50:1951;182-201.
89. Lev-Ram V., et al. A novel non-ataxic guinea pig strain with cerebrocortical and cerebellar abnormalities. Brain Res. 606:1993;325-331.
90. Bachevalier J. Medial temporal lobe structures and autism: a review of clinical and experimental findings. Neuropsychologia. 32:1994;627-648.
91. Bobnée S., et al. Effects of early midline cerebellar lesion on cognitive and emotional functions in the rat. Behav. Brain Res. 112:2000;107-117.
92. Wolterink G., et al. Early amygdala damage in the rat as a model for neurodevelopmental psychopathological disorders. Eur. Neuropsychopharmacol. 11:2001;51-59.
93. Ingram J.L., et al. Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicol. Teratol. 22:2000;319-324.
94. Pletnikov M.V., et al. Developmental brain injury associated with abnormal play behavior in neonatally Borna disease virus-infected Lewis rats: a model of autism. Behav. Brain Res. 100:1999;43-50.
95. Tropepe V., Sive H.L. Can zebrafish be used as a model to study the neurodevelopmental causes of autism? Genes Brain Behav. 2:2003;268-281.